Home » Topics » Regulatory » Patents

Patents
RSS

NPY antagonists from Thomae

July 25, 1997

Selective neuropeptide Y5 receptor antagonists described by Synaptic

July 25, 1997

Phosphodiesterase inhibitors from Schering-Plough

July 24, 1997

Asta prepares and evaluates targeted cytotoxic anthracycline analogues

July 24, 1997

Pierre Fabre prepares compounds for hypercholesterolemia/atherosclerosis

July 24, 1997

NPY antagonists developed at Thomae

July 24, 1997

Warner-Lambert describes compounds that modulate signal transduction pathways

July 23, 1997

Inhibitors of adhesion molecule expression and TNF release from Novartis

July 23, 1997

Novartis prepares orally active iron chelators

July 23, 1997

Schering AG describes AMPA antagonists

July 23, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...